EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$8.05
0.12 (1.51%)
▲
5d:
+0.0%
30d:
-1.23%
90d:
-35.24%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
EBS is down 3.2% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 208 OI. Call ratio: 100% View Scanner →
Strength: 6.6/10
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EBS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: EBS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$0.37
Based on -25.9% avg growth
INTRINSIC VALUE TODAY
$0.23
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $8.05, which is considered slightly low relative to its 30-day fair value range of $7.69 to $9.99. From a valuation perspective, the stock is trading at a premium (Forward PE: 35.0) compared to its historical average (9.0). At these levels, the market is pricing in 57.3% annual earnings growth.
Technical Outlook: Technically, EBS is in a downtrend. The price is currently testing key support at $7.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+49.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EBS is in a downtrend. The price is currently testing key support at $7.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+49.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$7.69 -
$9.99
Company Quality Score
58/100
(HOLD)
Options IV Signal
21th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 21th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 49.1% below Wall St target ($12.00)
- BULLISH: Expecting earnings turnaround to 57.3% growth with -23.6% revenue growth
Fair Price Analysis
30-Day Fair Range
$7.69 -
$9.99
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$1.50
(18.6%)
Support & Resistance Levels
Support Level
$7.85
Resistance Level
$8.45
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
35.00
Wall Street Target
$12.00
(+49.1%)
Revenue Growth (YoY)
-23.6%
Earnings Growth (YoY)
-55.8%
Profit Margin
7.1%
Valuation Premium vs History
+57.3% premium
PE vs Historical
35.0 vs 9.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+57.3%
(market-implied from PE analysis)
1-Year Target
$12.08
(+50%)
2-Year Target
$18.11
(+125%)
3-Year Target
$27.17
(+238%)
3-Yr Target (if PE normalizes)
(PE: 35→9)
PE COMPRESSION
$6.99
(-13%)
Significant PE compression expected
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.0, Growth: -55.8%)
$5.87
(+-27%)
Base:
(SPY PE: 22.4, Growth: -55.8%)
$3.75
(-53%)
Bear:
(PE: 9.0, Growth: -55.8%)
$1.51
(-81%)
📈
Valuation based on Current Earnings
Trailing PE: 8.81 | Current EPS (TTM): $0.93
Bull Case
$4.50
(-44%)
Analyst growth -50.0%, PE expands to 9.7
Base Case
$4.10
(-49%)
Market implied -50.0%, PE stable at 8.8
Bear Case
$5.57
(-31%)
Severe decline -20.0%, PE contracts to 7.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 6:35 PM ET
Data refreshes hourly during market hours. Next update: 7:35 PM
Data refreshes hourly during market hours. Next update: 7:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ronald Richard
SELL
21984 shares
2025-12-05
Coleen Glessner
SELL
30608 shares
2025-10-07
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
